COVID-19-Related Sarcoidosis

Attapon Cheepsattayakorn^{1,2,3,4}*, Ruangrong Cheepsattayakorn⁵ and Porntep Siriwanarangsun¹

¹Faculty of Medicine, Western University, Pathumtani Province, Thailand

²Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok, Thailand

³10th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand

⁴Department of Disease Control, Ministry of Public Health, Thailand

⁵Department of Pathology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand

*Corresponding Author

Attapon Cheepsattayakorn, 10th Zonal Tuberculosis and Chest Disease Center, 143 Sridornchai Road Changklan Muang Chiang Mai 50100 Thailand.

Submitted: 2023, Dec 29; **Accepted:** 2024, Jan 16; **Published:** 2024, Jan 22

Citation: Cheepsattayakorn, A., Cheepsattayakorn, R., Siriwanarangsun, P. (2024). COVID-19-Related Sarcoidosis. *Med Pharmacol OA*, 2(1), 01-04.

Several post-COVID-19 inflammatory disorders autoimmune diseases have been discovered [1] since global COVID-19 pandemic started [2]. Association between these diseases is still to be investigated [2]. Common genes between COVID-19 and sarcoidosis are demonstrated in Figure 1, 2 [3]. Nevertheless, sarcoidosis organ involvement, demographics, and type of sarcoidosis treatment at the time of COVID-19 diagnosis are related to hospital admission, non-invasive ventilation or high flow oxygenation, intubation [4]. A retrospective hospitalbased cohort study of 585 French sarcoidosis patients in 2017, demonstrated an estimate of a 5 % frequency of severe infections that resulting in hospital admission and death [5]. A typical HRCT feature in sarcoidosis is the presence of welldefined micronodules scattered along the broncho-vascular bundle, veins, fissures and pleura in a characteristic lymphatic distribution. Occasionally, "galaxy sign",a highly suggestive of pulmonary sarcoidosis (predominance of a mid-to-upper lung zones) may demonstrates conglomerate masses that are surrounded by a multitude of micronodules (Figure 3) [6].

Where VDR dominantly connected to 14 different kinds of drug, protein drug interaction network collected from DrugBank provides proper treatment. Vitamin D and some of its analogous compounds might play significant roles in modulating both COVID-19 and sarcoidosis conditions is indicated by this network (Figure 4) [3].

Besides sarcoidosis of lungs, symptomatic and accidental extrapulmonary sarcoidosis is also found around the world (Figure 5, 6, 7) [7-9].

In conclusion, hub gene identification might have significant roles in modulating sarcoidosis and COVID-19 infection. In the literature, cases with sarcoid-like granuloma have been reported very few. Sarcoid-like immune response to COVID-19 could be noncaseating granulomas due to short time from disease to develop granuloma.

Med Pharmacol OA, 2024 Volume 2 | Issue 1 | 1




Figure 1: Demonstrating a Venn diagram of commonly differentially expressed upregulated genes. Common 34 upregulated genes were identified from 2320 upregulated genes of COVID-19 infection and 227 upregulated genes of sarcoidosis [3].





Figure 2: Demonstrating protein-protein interactions (PPIs) network for common upregulated genes from COVID-19 and sarcoidosis. The light green color nodes indicate common upregulated genes. Network consists of 32 nodes and 102 edges [3].



Med Pharmacol OA, 2024 Volume 2 | Issue 1 | 2




Figure 3: Demonstrating irregularly marginated nodule surrounded by multiple small nodules ("Galaxy sign", yellow narrow), this is typical of sarcoidosis (a); ground-glass-like increased attenuation resulting from diffuse micronodules randomly distributed ("Miliary sarcoidosis") (b); enlarged and partially calcified (yellow narrows) bilateral hilar lymph nodes (c); fibrotic sarcoidosis with cystic changes and traction bronchiectases (yellow narrows) predominantly in the perihilar region and upper lobes. Nodular abnormalities are minimal/absent, but the appearance and the location of the fibrosis are very suggestive of the diagnosis of sarcoidosis (d) [6].




Figure 4: Demonstrating drugs protein interaction network [3].




Figure 5: Demonstrating isolated muscular sarcoidosis, revealed by hypercalcemia and 18F-FDG PET/CT [7].

Med Pharmacol OA, 2024 Volume 2 | Issue 1 | 3




Figure 6: 18F-FDG PET/MRI for Diagnosis and Treatment Efficacy Evaluation of Spinal Sarcoidosis [8].




Figure 7: Demonstrating FDG PET of Isolated Right Ventricular Sarcoidosis [9].

References

- Galeotti, C., & Bayry, J. (2020). Autoimmune and inflammatory diseases following COVID-19. Nature Reviews Rheumatology, 16(8), 413-414.
- Racil, H., Znegui, T., Maazoui, S., Touil, A., Habibech, S., Henda, N., & Chaouch, N. (2023). Can Coronavirus Disease 2019 Induce Sarcoidosis: A Case Report. Turkish Thoracic Journal/Turk Toraks Dergisi, 24(1).
- Mogal, M. R., Sompa, S. A., Junayed, A., Mahmod, M. R., Abedin, M. Z., & Sikder, M. A. (2022). Common genetic aspects between COVID-19 and sarcoidosis: A networkbased approach using gene expression data. Biochemistry and Biophysics Reports, 29, 101219.
- Nadeem O, Sharma A, Alaouie D, Bradley P, Ouellette D. (2021). Outcomes in Patients with Sarcoidosis Diagnosed with Covid-19. Chest. Oct;160(4):A1274
- Duréault, A., Chapelon, C., Biard, L., Domont, F., Savey, L., Bodaghi, B., ... & Saadoun, D. (2017). Severe infections

- in sarcoidosis: incidence, predictors and long-term outcome in a cohort of 585 patients. Medicine, 96(49).
- Bernardinello, N., Petrarulo, S., Balestro, E., Cocconcelli, E., Veltkamp, M., & Spagnolo, P. (2021). Pulmonary sarcoidosis: diagnosis and differential diagnosis. Diagnostics, 11(9), 1558.
- Dhomps, A., Foret, T., Streichenberger, N., Skanjeti, A., & Tordo, J. (2019). Isolated muscular sarcoidosis revealed by hypercalcemia and 18F-FDG PET/CT. Clinical Nuclear Medicine, 44(10), 824-825.
- Kaseb, A., Bessac, D., Frantzen, L., Herber, M., Poindron, V., & Imperiale, A. (2024). 18F-FDG PET/MRI for Diagnosis and Treatment Efficacy Evaluation of Spinal Sarcoidosis. Clinical Nuclear Medicine, 49(1), e28-e30.
- Siegel A, Hoegemann Savellano D. (2023). FDG PET of Isolated Right Ventricular Sarcoidosis. Clin Nucl Med, 48(2),184-185

Copyright: ©2024 Attapon Cheepsattayakorn, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.